...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Interesting Uptick

FYI. NYAS Symposium is ongoing. They are on a one hour lunch break now and then re-convene for the afternoon session. Good stuff so far on the basic science. Afternoon session is more on the therapeutic end.


Plenary Session II: Epigenetic Therapies

1:30 PM

Introduction
Dominique Verhelle, PhD, Third Rock Ventures

1:35 PM

Epigenetic Regulators as Dynamic Memory Devices
Michael Elowitz, PhD, California Institute of Technology

2:10 PM

EpiScience — Translating the Epigenetic Concept into Clinical Benefits
Daniel Vitt, PhD, 4SC

2:45 PM

New Horizons for BET Inhibition: Apabetalone for the Treatment of High-Risk Cardiovascular Disease
Ewelina Kulikowski, PhD, Resverlogix Corp

3:20 PM

Networking Coffee Break

3:50 PM

Preclinical Characterization of ZEN-3694, a Novel BET Bromodomain Inhibitor Entering Phase I Studies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Eric Campeau, PhD, Zenith Epigenetics

4:25 PM

Targeting Chromatin Regulatory Pathways in Cancer
Patrick Trojer, PhD, Constellation

5:00 PM

Poster Prize Presentation and Closing Remarks
George Zavoico, PhD, JonesTrading Institutional Services

5:10 PM

Networking Reception

6:00 PM

Adjourn

Share
New Message
Please login to post a reply